MAP2K7 and neoplasm: However, beside the direct effect of MEK inhibition on cancer cells, the authors showed that G-38963 (which is similar to the MEK inhibitor Cobimetinib) can increase the number of effector-phenotype antigen-specific CD8+ T-cells within the tumor and act on the tumor-infiltrating CD8+ T-cells’ biology and survival.